BC-2 (ATCC® CRL-2231)

Organism: Homo sapiens, human  /  Cell Type: B lymphocyte  /  Tissue: pleural effusion  /  Disease: lymphoma

Organism Homo sapiens, human
Tissue pleural effusion
Cell Type B lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 2 Cells contain EBV and KSHV (HHV-8) viral genomes

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease lymphoma
Age 31 years adult
Gender male
Ethnicity Caucasian
Applications

Transfection host

The BC-2 cell line allows in vitro culture of KSHV viral genomes.

It is also a practical source of KSHV DNA to be used as a positive control for screening tests.

Storage Conditions liquid nitrogen vapor phase
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
Derivation

BC-2 is a lymphoma cell line originated in 1992 by Ethel Cesarman and Giorgio Inghirami in the laboratory of Daniel M. Knowles.

The cells were derived from a pleural cavity based lymphomatous effusion.

Antigen Expression
CD45 +; EMA + (epithelial membrane antigen)
Comments

The cells contain two viral genomes: Epstein-Barr virus (EBV) and Kaposi sarcoma associated herpesvirus (KSHV, provisionally designed HHV-8).

KSHV is a recently identified and largely uncharacterized virus.

 

Complete Growth Medium RPMI 1640 medium, 80%; fetal bovine serum, 20%
Subculturing Cultures can be maintained by addition or replacement of medium. When replacing media, centrifuge cells and resuspend cell pellet in fresh medium at 4 to 5 x 105viable cells/mL. Maintain cultures at cell concentrations between 3 x 105 and 2 x 106 viable cells/mL.
Medium Renewal: Every 2 to 3 days
Cryopreservation
Complete growth medium, 95%; DMSO, 5%. Cell culture tested DMSO is available as ATCC Catalog No. 4-X.
Population Doubling Time 48 to 72 hrs
Name of Depositor Cornell Res. Fndn., Inc.
U.S. Patent Number
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
References

Moore PS, et al. Primary characterization of a herpesvirus agent associated with Kaposi's sarcoma. J. Virol. 70: 549-558, 1996. PubMed: 8523568

Cesarman E, et al. In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA sequences. Blood 86: 2708-2714, 1995. PubMed: 7670109

Chadburn A, et al. CD30 (Ki-1) positive anaplastic large cell lymphomas in individuals infected with the human immunodeficiency virus. Cancer 72: 3078-3090, 1993. PubMed: 8221575

Cesarman E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS- related body-cavity-based lymphomas. N. Engl. J. Med. 332: 1186-1191, 1995. PubMed: 7700311

Cesarman E, et al. KSHV positive cell lines. US Patent 5,908,773 dated Jun 1 1999

Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC.

Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988.

Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC.

Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online.

Basic Documentation
References

Moore PS, et al. Primary characterization of a herpesvirus agent associated with Kaposi's sarcoma. J. Virol. 70: 549-558, 1996. PubMed: 8523568

Cesarman E, et al. In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA sequences. Blood 86: 2708-2714, 1995. PubMed: 7670109

Chadburn A, et al. CD30 (Ki-1) positive anaplastic large cell lymphomas in individuals infected with the human immunodeficiency virus. Cancer 72: 3078-3090, 1993. PubMed: 8221575

Cesarman E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS- related body-cavity-based lymphomas. N. Engl. J. Med. 332: 1186-1191, 1995. PubMed: 7700311

Cesarman E, et al. KSHV positive cell lines. US Patent 5,908,773 dated Jun 1 1999

Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC.

Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988.

Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC.

Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online.